Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Breast 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Doxycycline × Dermatologic × Clear all
NCT02341209 2021-04-27

CTCL

Rochester General Hospital

Phase 2 Terminated
1 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡